AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Article references detail studies on cancer treatment, survivorship, quality of life, pain management, and integrative medicine, highlighting various aspects of cancer care and treatment outcomes.

Darolutamide plus androgen-deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) by 46% versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with consistent benefits across subgroups and a favorable safety profile.

New therapy, ponsegromab, shows promise in treating cachexia, improving weight, appetite, and quality of life in cancer patients, according to a study published in The New England Journal of Medicine.

LeJeunesse, diagnosed with de novo metastatic breast cancer, advocates for cancer research through her podcast 'Cancer for Breakfast' and attends events like the Value in Cancer Care Summit. She is a clinical trials enthusiast and collaborates with her oncologist, Dr. Rachel Yung, who highlights the importance of patient involvement in research design. LeJeunesse also created the Breast Cancer Care-a-van, a mobile distribution center for cancer information and support.

The cell-free DNA isolation and extraction market is projected to grow from $1.81 billion in 2023 to $2.49 billion by 2028, driven by increasing cancer prevalence, advancements in genomics, and demand for personalized medicine. Key trends include product innovation, strategic partnerships, and technological advancements in DNA extraction techniques.

NMPA grants Breakthrough Therapy Designation to Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone for relapsed or refractory multiple myeloma, based on phase III DREAMM-7 trial results showing significant PFS improvements. A positive OS trend was observed but not statistically significant at interim analysis.

Regeneron's melanoma combo therapy, fianlimab plus Libtayo, shows 25% complete response and 57% objective response rates after 23 months in a Phase I trial, with ongoing Phase III studies.

Kisqali (ribociclib) + endocrine therapy (ET) reduces recurrence risk by 28.5% beyond 3 years in HR+/HER2- early breast cancer, with consistent benefits across subgroups, including node-negative disease. Safety remains consistent with low-grade adverse events. Results to be presented at ESMO; FDA action expected in Q3.

Adjuvant pembrolizumab (Keytruda) continues to show improved disease-free survival (DFS) vs observation in high-risk muscle-invasive urothelial carcinoma patients after 45 months of follow-up, according to the phase 3 A031501 AMBASSADOR trial. Median DFS was 29.6 months in the pembrolizumab arm vs 14.2 months in the observation arm, with DFS benefits observed regardless of PD-L1 expression and lymph node status.

23ME-00610, an anti-CD200R1 antibody, shows preliminary clinical benefit in clear-cell renal-cell carcinoma with one confirmed partial response. Higher CD200 tumor expression and human genetics correlate with increased clinical benefit, suggesting potential as patient selection biomarkers. Greater response in 'cold' tumors indicates opportunity for patients unresponsive to PD-1/PD-L1 inhibitors.